ClinicalTrials.gg
Not yet recruitingNCT06863766Updated Apr 3, 2025

Effects of Milk Powder Intervention on Blood Glucose Control and Fluctuation in Middle-aged and Elderly People With Pre-diabetes

An interventional study of fortified formula milk powder group and regular milk powder group in Pre-diabetes, sponsored by Huilian Zhu. Not yet recruiting. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Huilian Zhu · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This study aims to conduct a 8-week intervention involving one formula milk powder for middle-aged and elderly individuals with pre-diabetes, assessing its impact on blood glucose control and fluctuations in comparison to interventions using regular milk powder.

02

Conditions studied

  • Pre-diabetes

Browse trials for

03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

This study's planned enrollment of 110 is above the median of 56 across 661 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Huilian Zhu is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 40 and 75 years, regardless of gender.
  2. Impaired fasting glucose (5.6 mmol/L ≤ FPG \< 6.9 mmol/L) or (HbA1c) between 5.7-6.4% (39-47 mmol/mol).
  3. Resided in Guangzhou for the past six months and no plans to relocate or travel outside the city in the next month.
  4. Signed form and voluntarily agreed to participate in the project.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a confirmed diagnosis of diabetes who are currently taking glucose-lowering medications (e.g., insulin, GLP-1 receptor agonists, or SGLT2 inhibitors).
  2. Individuals with lactose intolerance or dairy product intolerance.
  3. Pregnant, planning to become pregnant within the next three months, or currently breastfeeding.
  4. Weight change > 5% in the past three months or plans to lose weight or change dietary habits.
  5. Alcohol consumption > 40g/day.
  6. Individuals with communication barriers, cognitive impairments, or other conditions that may prevent them from completing the study procedures.
  7. Severe diseases that may affect participation in the study, including but not limited to endocrine disorders, severe cardiovascular or cerebrovascular diseases, cancer, metabolic diseases, etc.
  8. Participation in or current involvement in other clinical trials within the past three months.
  9. No use of antibiotic medications within the past three months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    fortified formula milk powder group

    Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.

    Dietary Supplement: fortified formula milk powder group

  • Placebo comparator
    regular milk powder group

    Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.

    Dietary Supplement: regular milk powder group

Interventions

  • Dietary supplementfortified formula milk powder group

    Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.

  • Dietary supplementregular milk powder group

    Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.

06

What researchers measure

Primary outcomes

  1. fasting blood glucose

    At baseline, and 8 weeks, investigators will use automatic electrochemiluminescence analyzer to examine fasting blood glucose.

    Time frame: up to 8 weeks

  2. 2h-piAUC after standardized breakfast

    the positive increment of area under curve in 2 hours after standardized breakfast standardized breakfast, measured by continuous glucose monitoring at baseline, and 8 weeks.

    Time frame: up to 8 weeks

  3. TIR (time in range)

    TIR refers to the time when blood glucose is controlled within a reasonable ( target ) range (3.9\~10.0 mmol/L), measured by continuous glucose monitoring at baseline and 8 weeks.

    Time frame: up to 8 weeks

Secondary outcomes

  1. HbA1c

    At baseline, and 8 weeks, investigators will use automatic electrochemiluminescence analyzer to examine HbA1c.

    Time frame: up to 8 weeks

  2. weight

    At baseline, and 8 weeks, investigators will examine weight.

    Time frame: up to 8 weeks

  3. intestinal bacteria

    At baseline, and 8 weeks, investigators will use 16S rRNA pyrosequencing to examine intestinal bacteria.

    Time frame: up to 8 weeks

  4. lipid metabolism

    At baseline, and 8 weeks, investigators will use automatic electrochemiluminescence analyzer to examine total cholesterol, low density lipoprotein, high density lipoprotein, triglyceride.

    Time frame: up to 8 weeks

  5. sleep quality

    At baseline, and 8 weeks, investigators will use the Pittsburgh sleep quality index scale to examine sleep quality.

    Time frame: up to 8 weeks

  6. blood pressure

    At baseline, and 8 weeks, investigators will test the systolic blood pressure and diastolic blood pressure using automatic digital blood pressure monitor

    Time frame: up to 8 weeks

  7. Continuous Glucose Monitoring (CGM) Data

    At baseline, and 8 weeks, investigators will using Continuous Glucose Monitoring (CGM) to monitor the glucose level of participants

    Time frame: up to 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Dec 2025, 8 months later.

Of 254 non-industry interventional studies with no phase under Glucose Intolerance, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 8 months is below that.

Counting every sponsor, half of 286 studies reached it within 26 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 7, 2025
StartEst.
Apr 10, 2025
Primary completionEst.
Dec 20, 2025
CompletionEst.
Mar 30, 2026
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06863766
Lead sponsor
Huilian Zhu
Responsible party
Huilian Zhu (Professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Mar 7, 2025
Start date
Apr 10, 2025 (estimated)
Primary completion
Dec 20, 2025 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Apr 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion